Biotech company executives meeting recently in Boston, were reportedly concerned about the growing buy-out trend among area businesses. While small, underfunded companies and venture-backed start-ups welcome the infusion of cash provided by a large, single company takeover, others would apparently prefer funding by a number of institutional and individual investors. The CEO of Alkermes Inc., which is marketing a drug that treats alcohol and opioid dependence, was quoted as saying, “It’s a big concern. But there’s not a hell of a lot you can do about it except to make yourself look unattractive.” According to CEO Matthew Emmens of Vertex Pharmaceuticals, Inc., “It’s not going to be your decision. It’s going to be the shareholders’ decision. Somebody either comes up and writes you a check, or they don’t.” The trend is apparently attributed to the regulatory environment, described as “unforgiving,” and the dearth of new drugs coming out of the world’s largest pharmaceutical companies. See The Boston Globe, April 13, 2011.